诺沃·诺迪斯克(Novo Nordisk)和赫姆斯(Hims & hers)结束诉讼, 同意透过他的远程保健平台出售Wegovy。 Novo Nordisk and Hims & Hers end lawsuit, agreeing to sell Wegovy via Hims’ telehealth platform.

诺沃·诺迪斯克(Novo Nordisk)和赫姆斯及赫姆斯健康组织(Hims & her Health)已经解决了他们关于减重药物的法律纠纷,诺沃同意通过赫姆斯远程保健平台出售包括韦戈维在内的药品。 Novo Nordisk and Hims & Hers Health have settled their legal dispute over weight-loss drugs, with Novo agreeing to sell its medications, including Wegovy, through Hims’ telehealth platform. 这笔交易于2026年2月结束, 由Novo提出诉讼, 指控他推销一个复合版本的Wegovy, 声称这违反了专利权, 引起林业发展局的担忧。 The deal ends a February 2026 lawsuit filed by Novo over Hims’ marketing of a compounded version of Wegovy, which it claimed infringed patents and raised FDA concerns. 预计不久即将宣布的这一伙伴关系标志着从冲突转向协作,通过一家主要的直接对消费者的保健提供者,扩大获得林业发展局核准的减重治疗的机会。 The partnership, expected to be announced soon, marks a shift from conflict to collaboration, expanding access to FDA-approved weight-loss treatments through a major direct-to-consumer health provider.